Structure identification and elucidation of mosapride metabolites in human urine, feces and plasma by ultra performance liquid chromatography-tandem mass spectrometry method

Xenobiotica

Volumn 44, Issue 8, 2014, Pages 734-742

  Sun, Xiaohong ^a,b   Zhao, Longshan ^a   Niu, Lili ^a   Qin, Feng ^a   Lu, Xiumei ^a   Xiong, Zhili ^a   Li, Famei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

Author keywords

Human; Metabolism; Mosapride; UPLC ESI MS MS

Indexed keywords

DES FLUOROBENZYL MOSAPRIDE; DRUG METABOLITE; MORPHOLINE; MOSAPRIDE; MOSAPRIDE N OXIDE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; MORPHOLINE DERIVATIVE;

ADULT; ARTICLE; DEALKYLATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; NORMAL HUMAN; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; BLOOD; CHEMISTRY; CLINICAL TRIAL; FECES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; RAT; URINE;

ADULT; ANIMALS; BENZAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MORPHOLINES; RATS; TANDEM MASS SPECTROMETRY;

EID: 84904018013     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.880201     Document Type: Article

References (18)

1. Amir SY, Upendra AA, Murali P, et al. (2013). Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS. Xenobiotica 43: 1073-83.
2. Asai H, Udaka F, Hirano M, et al. (2005). Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord 11: 499-502. (Pubitemid 41627841)
3. Bailey J, Thew M, Balls M. (2013). An analysis of the use of dogs in predicting human toxicology and dog safety. Altern Lab Anim 41: 335-50.
4. Clarke NJ, Rindgen D, Korfmacher WA, et al. (2001). Systematic LC/MS metabolite identification in drug discovery. Anal Chem 73: 430A-9A. (Pubitemid 32862353)
5. Curran MP, Robinson DM. (2008). Mosapride in gastrointestinal disorders. Drugs 68: 981-91.
6. Dai HX, Wang MM, Li XR, et al. (2008). Structural elucidation of in vitro and in vivo metabolites of cryptotanshinone by HPLC- DAD-ESI-MSn. J Pharm Biomed Anal 50: 27-34.
7. Hsieh Y, Korfmacher WA. (2006). Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening. Curr Drug Metab 7: 479-89.
8. Liu Z, Sakakibara R, Odaka T, et al. (2005). Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 20: 680-6. (Pubitemid 41051779)
9. Matsumoto S, Tagawa M, Hatoyama T, et al. (1993a). Absorption, distribution, metabolism and excretion of [carbonyl-14C]mosapride citrate after repeated oral administration in rats. Arzneimittelforschung 43: 1103-8. (Pubitemid 23311889)
10. Matsumoto S, Yoshida K, Itogawa A, et al. (1993b). Metabolism of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys. Arzneimittelforschung 43: 1095-102. (Pubitemid 23311888)
11. Nassar AEF, Talaat RE, Kamel AM. (2006). The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet? Curr Opin Drug Discov Devel 9: 61-74. (Pubitemid 43099076)
12. Oliveira EJ, Watson DG. (2000). Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed Chromatogr 14: 351-72.
13. Pedraglio S, Rozio MG, Misiano P, et al. (2007). New perspectives in bio-analytical techniques for preclinical characterization of a drug candidate: UPLC-MS/MS in in vitro metabolism and pharmacokinetic studies. J Pharm Biomed Anal 44: 665-73. (Pubitemid 47039194)
14. Sakashita M, Yamaguchi T, Miyazaki H, et al. (1993). Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung 43: 867-72. (Pubitemid 23254936)
15. Sun XH, Niu LL, Li XQ, et al. (2009a). Characterization of metabolic profile of mosapride citrate in rat and identification of two new metabolites: Mosapride N-oxide and morpholine ringopened mosapride by UPLC-ESI-MS/MS. J Pharm Biomed Anal 50: 27-34.
16. Sun XH, Man F, Pang LY, et al. (2009b). Fungal biotransformation of mosapride by Cunninghamella elegans. J Mol Catal B: Enzym 59: 82-9.
17. U.S. Food and Drug Administration. (2008). Guidance for industry safety testing of drug metabolites. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available from: http://www.fda.gov/downloads/ drugs/guidancecomplianceregulatoryi nformation/guidances/ucm079266.pdf [last accessed February 2008].
18. Yoshida N. (1999). Pharmacological effects of the gastroprokinetic agent mosapride citrate. Nippon Yakurigaku Zasshi 113: 299-307. (Pubitemid 29254500)